CCCC Latest Press Releases

-- August 11, 2026 --

C4 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights Globe Newswire 7:00 AM

-- August 10, 2026 --

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:01 PM

-- June 11, 2026 --

C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population Globe Newswire 7:00 AM

-- May 20, 2026 --

C4 Therapeutics to Participate in Upcoming Conferences Globe Newswire 7:00 AM

-- May 18, 2026 --

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:01 PM

-- May 12, 2026 --

C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights Globe Newswire 7:00 AM

-- April 9, 2026 --

C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs) Globe Newswire 6:59 AM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software